Free from Publisher

RV568, a narrow-spectrum kinase inhibitor with p38 MAPK-α and-γ selectivity, suppresses COPD inflammation

CE Charron, P Russell, K Ito, S Lea… - European …, 2017 - Eur Respiratory Soc
Novel anti-inflammatory approaches targeting chronically activated kinase pathways in
chronic obstructive pulmonary disease (COPD) are needed. We evaluated RV568, a p38 …
被引用次数：46 相关文章

RV568, a narrow-spectrum kinase inhibitor with p38 MAPK-α and-γ selectivity, suppresses COPD inflammation

CE Charron, P Russell, K Ito, S Lea… - European …, 2017 - research.manchester.ac.uk
Novel anti-inflammatory approaches targeting chronically activated kinase pathways in
chronic obstructive pulmonary disease (COPD) are needed. We evaluated RV568, a p38 …

RV568, a narrow-spectrum kinase inhibitor with p38 MAPK-α and-γ selectivity, suppresses COPD inflammation.

CE Charron, P Russell, K Ito, S Lea… - The European …, 2017 - europepmc.org
Novel anti-inflammatory approaches targeting chronically activated kinase pathways in
chronic obstructive pulmonary disease (COPD) are needed. We evaluated RV568, a p38 …

RV568, a narrow-spectrum kinase inhibitor with p38 MAPK-α and-γ selectivity, suppresses COPD inflammation

CE Charron, P Russell, K Ito, S Lea, Y Kizawa… - European Respiratory …, 2017 - cir.nii.ac.jp
抄録< jats: p> Novel anti-inflammatory approaches targeting chronically activated kinase
pathways in chronic obstructive pulmonary disease (COPD) are needed. We evaluated …

RV568, a narrow-spectrum kinase inhibitor with p38 MAPK-α and-γ selectivity, suppresses COPD inflammation

CE Charron, P Russell, K Ito, S Lea, Y Kizawa… - 2017 - pubmed.ncbi.nlm.nih.gov
Novel anti-inflammatory approaches targeting chronically activated kinase pathways in
chronic obstructive pulmonary disease (COPD) are needed. We evaluated RV568, a p38 …